 CHARLOTTESVILLE, Va., June 24, 2021 GLOBE NEWSWIRE -- Adial Pharmaceuticals, Inc. NASDAQ: ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has received correspondence related to its request for Fast Track Designation from the U.S. Food and Drug Administration FDA for its drug candidate, AD04, for the treatment of Alcohol Use Disorder AUD in pediatric patients and adult patients with Alcoholic Liver Disease ALD with select polymorphisms of the serotonin transporter and receptor genes. While AD04 is being developed and undergoing a pivotal Phase 3 trial to treat any adult with AUD with the targeted genetics, Adial believes AD04 holds the potential to effectively and safely treat AUD patients that are adolescents or have ALD. 